Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

A novel neuromodulation technique for the rehabilitation of balance and gait: A case study.

Cofré Lizama LE, Bastani A, Panisset MG, Drummond K, Khan F, Galea MP.

J Clin Neurosci. 2018 May 12. pii: S0967-5868(18)30662-3. doi: 10.1016/j.jocn.2018.04.077. [Epub ahead of print]

PMID:
29764702
2.

Bedside quantification of fat-free mass in acute spinal cord injury using bioelectrical impedance analysis: a psychometric study.

Panisset MG, Desneves K, Ward LC, Rafferty J, Rodi H, Roff G, El-Ansary D, Galea MP.

Spinal Cord. 2018 Apr;56(4):355-365. doi: 10.1038/s41393-017-0035-1. Epub 2017 Dec 28.

PMID:
29284797
3.

Cranial nerve non-invasive neuromodulation improves gait and balance in stroke survivors: A pilot randomised controlled trial.

Galea MP, Cofré Lizama LE, Bastani A, Panisset MG, Khan F.

Brain Stimul. 2017 Nov - Dec;10(6):1133-1135. doi: 10.1016/j.brs.2017.08.011. Epub 2017 Sep 20. No abstract available.

PMID:
28923502
4.

Prevalence of Convergence Insufficiency-Type Symptomatology in Parkinson's Disease.

Law C, Chriqui E, Kergoat MJ, Leclerc BS, Panisset M, Irving EL, Postuma RB, Chouinard S, Kergoat H.

Can J Neurol Sci. 2017 Sep;44(5):562-566. doi: 10.1017/cjn.2017.39.

PMID:
28862105
5.

REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson's Disease.

Jozwiak N, Postuma RB, Montplaisir J, Latreille V, Panisset M, Chouinard S, Bourgouin PA, Gagnon JF.

Sleep. 2017 Aug 1;40(8). doi: 10.1093/sleep/zsx101.

6.

Orthoptic Treatment of Convergence Insufficiency in Parkinson's Disease: A Case Series.

Kergoat H, Law C, Chriqui E, Kergoat MJ, Leclerc BS, Panisset M, Postuma R, Irving EL.

Gerontol Geriatr Med. 2017 Apr 11;3:2333721417703735. doi: 10.1177/2333721417703735. eCollection 2017 Jan-Dec.

7.

Teneurin transmembrane protein 4 is not a cause for essential tremor in a Canadian population.

Houle G, Schmouth JF, Leblond CS, Ambalavanan A, Spiegelman D, Laurent SB, Bourassa CV, Panisset M, Chouinard S, Dupré N, Vilariño-Güell C, Rajput A, Dion PA, Rouleau GA.

Mov Disord. 2017 Feb;32(2):292-295. doi: 10.1002/mds.26753. Epub 2017 Feb 3.

PMID:
28158909
8.

Establishing a Standard of Care for Deep Brain Stimulation Centers in Canada.

Panisset M, Picillo M, Jodoin N, Poon YY, Valencia-Mizrachi A, Fasano A, Munhoz R, Honey CR.

Can J Neurol Sci. 2017 Mar;44(2):132-138. doi: 10.1017/cjn.2016.409. Epub 2016 Nov 22.

PMID:
27873569
9.

Open-Label Study of Sleep Disturbances in Patients with Parkinson's Disease Treated with Rasagiline.

Panisset M, Stril JL, Bélanger M, Lehoux G, Coffin D, Chouinard S.

Can J Neurol Sci. 2016 Nov;43(6):809-814.

PMID:
27827298
10.

Genome-wide association study in essential tremor identifies three new loci.

Müller SH, Girard SL, Hopfner F, Merner ND, Bourassa CV, Lorenz D, Clark LN, Tittmann L, Soto-Ortolaza AI, Klebe S, Hallett M, Schneider SA, Hodgkinson CA, Lieb W, Wszolek ZK, Pendziwiat M, Lorenzo-Betancor O, Poewe W, Ortega-Cubero S, Seppi K, Rajput A, Hussl A, Rajput AH, Berg D, Dion PA, Wurster I, Shulman JM, Srulijes K, Haubenberger D, Pastor P, Vilariño-Güell C, Postuma RB, Bernard G, Ladwig KH, Dupré N, Jankovic J, Strauch K, Panisset M, Winkelmann J, Testa CM, Reischl E, Zeuner KE, Ross OA, Arzberger T, Chouinard S, Deuschl G, Louis ED, Kuhlenbäumer G, Rouleau GA.

Brain. 2016 Dec;139(Pt 12):3163-3169. Epub 2016 Oct 20.

11.

Medical Management of Parkinson's Disease after Initiation of Deep Brain Stimulation.

Fasano A, Appel-Cresswell S, Jog M, Zurowkski M, Duff-Canning S, Cohn M, Picillo M, Honey CR, Panisset M, Munhoz RP.

Can J Neurol Sci. 2016 Sep;43(5):626-34. doi: 10.1017/cjn.2016.274. Review.

PMID:
27670207
12.

Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia.

Munhoz RP, Picillo M, Fox SH, Bruno V, Panisset M, Honey CR, Fasano A.

Can J Neurol Sci. 2016 Jul;43(4):462-71. doi: 10.1017/cjn.2016.35. Epub 2016 May 3. Review.

PMID:
27139127
13.

Deep Brain Stimulation Target Selection for Parkinson's Disease.

Honey CR, Hamani C, Kalia SK, Sankar T, Picillo M, Munhoz RP, Fasano A, Panisset M.

Can J Neurol Sci. 2017 Jan;44(1):3-8. doi: 10.1017/cjn.2016.22. Epub 2016 Mar 15. Review.

PMID:
26976064
14.

Electroencephalographic prodromal markers of dementia across conscious states in Parkinson's disease.

Latreille V, Carrier J, Gaudet-Fex B, Rodrigues-Brazète J, Panisset M, Chouinard S, Postuma RB, Gagnon JF.

Brain. 2016 Apr;139(Pt 4):1189-99. doi: 10.1093/brain/aww018. Epub 2016 Feb 16.

15.

A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists.

Huynh NT, Sid-Otmane L, Panisset M, Huot P.

Can J Neurol Sci. 2016 Nov;43(6):859-860. Epub 2016 Feb 4. No abstract available.

PMID:
26842385
16.

Brain Connectivity Alterations Are Associated with the Development of Dementia in Parkinson's Disease.

Bertrand JA, McIntosh AR, Postuma RB, Kovacevic N, Latreille V, Panisset M, Chouinard S, Gagnon JF.

Brain Connect. 2016 Apr;6(3):216-24. doi: 10.1089/brain.2015.0390.

PMID:
26708056
17.

Observational Study of the Relation between Parkinson's Disease and Sleep Apnea.

Béland SG, Postuma RB, Latreille V, Bertrand JA, Panisset M, Chouinard S, Wolfson C, Gagnon JF.

J Parkinsons Dis. 2015;5(4):805-11. doi: 10.3233/JPD-150602.

PMID:
26407040
18.

Does early exercise attenuate muscle atrophy or bone loss after spinal cord injury?

Panisset MG, Galea MP, El-Ansary D.

Spinal Cord. 2016 Feb;54(2):84-92. doi: 10.1038/sc.2015.150. Epub 2015 Sep 8. Review.

PMID:
26345485
19.

Development and evaluation of a dyadic intervention for elderly couples living with moderate-stage Parkinson disease.

Beaudet L, Ducharme F, L'Écuyer N, Chouinard S, Jodoin N, Panisset M.

Appl Nurs Res. 2015 Nov;28(4):e21-7. doi: 10.1016/j.apnr.2015.02.004. Epub 2015 Feb 26.

PMID:
26324119
20.

Sleep spindles in Parkinson's disease may predict the development of dementia.

Latreille V, Carrier J, Lafortune M, Postuma RB, Bertrand JA, Panisset M, Chouinard S, Gagnon JF.

Neurobiol Aging. 2015 Feb;36(2):1083-90. doi: 10.1016/j.neurobiolaging.2014.09.009. Epub 2014 Sep 18.

PMID:
25442116
21.

Physical activity in advanced Parkinson's disease: impact of subthalamic deep brain stimulation.

Daneault JF, Sadikot AF, Barbat-Artigas S, Aubertin-Leheudre M, Jodoin N, Panisset M, Duval C.

J Parkinsons Dis. 2015;5(1):85-93. doi: 10.3233/JPD-140426.

PMID:
25361545
22.

Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).

Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J; STACCATO study investigators.

Pharmacotherapy. 2014 Dec;34(12):1250-8. doi: 10.1002/phar.1500. Epub 2014 Oct 14.

PMID:
25314256
23.

Increased Prevalence of Non-motor Symptoms in Essential Tremor.

Lacerte A, Chouinard S, Jodoin N, Bernard G, Rouleau GA, Panisset M.

Tremor Other Hyperkinet Mov (N Y). 2014 Sep 2;4:162. doi: 10.7916/D82V2D91. eCollection 2014.

24.

Predictors of dementia in Parkinson disease: a prospective cohort study.

Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M, Montplaisir J, Postuma RB.

Neurology. 2014 Sep 30;83(14):1253-60. doi: 10.1212/WNL.0000000000000842. Epub 2014 Aug 29.

25.

Subthalamic stimulation improves motor function but not home and neighborhood mobility.

Daneault JF, Duval C, Barbat-Artigas S, Aubertin-Leheudre M, Jodoin N, Panisset M, Sadikot AF.

Mov Disord. 2014 Dec;29(14):1816-9. doi: 10.1002/mds.25911. Epub 2014 May 22.

PMID:
24849309
26.

Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's disease.

Moonen AJ, Wijers A, Leentjens AF, Christine CW, Factor SA, Juncos J, Lyness JM, Marsh L, Panisset M, Pfeiffer R, Rottenberg D, Serrano Ramos C, Shulman L, Singer C, Slevin J, McDonald W, Auinger P, Richard IH.

Parkinsonism Relat Disord. 2014 Jun;20(6):644-6. doi: 10.1016/j.parkreldis.2014.02.025. Epub 2014 Mar 18.

PMID:
24679737
27.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
28.

Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?

Daneault JF, Carignan B, Sadikot AF, Panisset M, Duval C.

BMC Med. 2013 Mar 20;11:76. doi: 10.1186/1741-7015-11-76. Review.

29.

Exome sequencing identifies FUS mutations as a cause of essential tremor.

Merner ND, Girard SL, Catoire H, Bourassa CV, Belzil VV, Rivière JB, Hince P, Levert A, Dionne-Laporte A, Spiegelman D, Noreau A, Diab S, Szuto A, Fournier H, Raelson J, Belouchi M, Panisset M, Cossette P, Dupré N, Bernard G, Chouinard S, Dion PA, Rouleau GA.

Am J Hum Genet. 2012 Aug 10;91(2):313-9. doi: 10.1016/j.ajhg.2012.07.002. Epub 2012 Aug 2.

30.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group.

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

31.

Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study.

Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, Panisset M, Gagnon JF.

Mov Disord. 2012 May;27(6):720-6. doi: 10.1002/mds.24939. Epub 2012 Feb 9.

PMID:
22322798
32.

Glucocerebrosidase mutations in a French-Canadian Parkinson's disease cohort.

Noreau A, Rivière JB, Diab S, Dion PA, Panisset M, Soland V, Jodoin N, Langlois M, Chouinard S, Dupré N, Rouleau GA.

Can J Neurol Sci. 2011 Sep;38(5):772-3. No abstract available.

PMID:
21856586
33.

LINGO1 variants in the French-Canadian population.

Bourassa CV, Rivière JB, Dion PA, Bernard G, Diab S, Panisset M, Chouinard S, Dupré N, Fournier H, Raelson J, Belouchi M, Rouleau GA.

PLoS One. 2011 Jan 11;6(1):e16254. doi: 10.1371/journal.pone.0016254.

34.

Chylomicron retention disease: dystonia as a new clinical feature.

Bernard G, Panisset M, Sadikot AF, Chouinard S.

Mov Disord. 2010 Aug 15;25(11):1755-6. doi: 10.1002/mds.23165. No abstract available.

PMID:
20589877
35.

Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis.

Odier C, Nguyen DK, Panisset M.

J Neurol. 2010 Jul;257(7):1176-80. doi: 10.1007/s00415-010-5486-7. Epub 2010 Feb 11.

PMID:
20148334
36.

Executive functions in frontotemporal dementia and Lewy body dementia.

Johns EK, Phillips NA, Belleville S, Goupil D, Babins L, Kelner N, Ska B, Gilbert B, Inglis G, Panisset M, de Boysson C, Chertkow H.

Neuropsychology. 2009 Nov;23(6):765-77. doi: 10.1037/a0016792.

PMID:
19899835
37.

Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease.

Gagnon JF, Vendette M, Postuma RB, Desjardins C, Massicotte-Marquez J, Panisset M, Montplaisir J.

Ann Neurol. 2009 Jul;66(1):39-47. doi: 10.1002/ana.21680.

PMID:
19670440
38.

Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.

Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A; FIRST-STEP Study Group.

Mov Disord. 2009 Mar 15;24(4):541-50. doi: 10.1002/mds.22343.

PMID:
19058133
39.

Impact of standard of care for psychosis in Parkinson disease.

Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE.

J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1413-5. doi: 10.1136/jnnp.2008.153163. No abstract available.

PMID:
19010958
40.

Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .

Jog M, Panisset M, Suchowersky O, Réhel B, Schecter R.

Curr Med Res Opin. 2008 Nov;24(11):3207-15. doi: 10.1185/03007990802430518 . Epub 2008 Oct 14.

PMID:
18922214
41.

Manganese cumulative exposure and symptoms: a follow-up study of alloy workers.

Bouchard M, Mergler D, Baldwin ME, Panisset M.

Neurotoxicology. 2008 Jul;29(4):577-83. doi: 10.1016/j.neuro.2008.04.013. Epub 2008 May 2.

PMID:
18562007
42.

Neural substrates of cognitive skill learning in Parkinson's disease.

Beauchamp MH, Dagher A, Panisset M, Doyon J.

Brain Cogn. 2008 Nov;68(2):134-43. doi: 10.1016/j.bandc.2008.03.008. Epub 2008 May 5.

PMID:
18456379
43.

Absence of cognitive deficits following deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease.

Fraraccio M, Ptito A, Sadikot A, Panisset M, Dagher A.

Arch Clin Neuropsychol. 2008 Jul;23(4):399-408. doi: 10.1016/j.acn.2008.02.001. Epub 2008 Apr 3.

44.

REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia.

Vendette M, Gagnon JF, Décary A, Massicotte-Marquez J, Postuma RB, Doyon J, Panisset M, Montplaisir J.

Neurology. 2007 Nov 6;69(19):1843-9.

PMID:
17984452
45.

LRRK2 screening in a Canadian Parkinson's disease cohort.

Grimes DA, Racacho L, Han F, Panisset M, Bulman DE.

Can J Neurol Sci. 2007 Aug;34(3):336-8.

PMID:
17803033
46.

Is there seasonal variation in risk of Parkinson's disease?

Postuma RB, Wolfson C, Rajput A, Stoessl AJ, Martin WR, Suchowersky O, Chouinard S, Panisset M, Jog MS, Grimes DA, Marras C, Lang AE.

Mov Disord. 2007 Jun 15;22(8):1097-101.

PMID:
17486603
47.

The error negativity in nonmedicated and medicated patients with Parkinson's disease.

Stemmer B, Segalowitz SJ, Dywan J, Panisset M, Melmed C.

Clin Neurophysiol. 2007 Jun;118(6):1223-9. Epub 2007 Mar 29.

PMID:
17398147
48.

Mood stability during acute stimulator challenge in Parkinson's disease patients under long-term treatment with subthalamic deep brain stimulation.

Berney A, Panisset M, Sadikot AF, Ptito A, Dagher A, Fraraccio M, Savard G, Pell M, Benkelfat C.

Mov Disord. 2007 Jun 15;22(8):1093-6.

PMID:
17394245
49.

Neurobehavioral functioning after cessation of manganese exposure: a follow-up after 14 years.

Bouchard M, Mergler D, Baldwin M, Panisset M, Bowler R, Roels HA.

Am J Ind Med. 2007 Nov;50(11):831-40.

PMID:
17096374
50.

REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease.

Gagnon JF, Petit D, Fantini ML, Rompré S, Gauthier S, Panisset M, Robillard A, Montplaisir J.

Sleep. 2006 Oct;29(10):1321-5.

PMID:
17068986

Supplemental Content

Loading ...
Support Center